What Is Medicare?

Opening Hook

When Warren Buffett calls healthcare costs "the tapeworm of American economic competitiveness," he's talking largely about Medicare. This $1.02 trillion federal program—representing nearly 15% of total federal spending—doesn't just insure 65 million Americans. It sets reimbursement rates that ripple through every corner of the healthcare economy, making it the single most important factor in determining which medical device companies thrive, which hospitals stay profitable, and which pharmaceutical stocks deliver alpha.

What It Actually Means

Medicare is the federal health insurance program that covers Americans aged 65 and older, plus certain disabled individuals and those with end-stage renal disease. Think of it as the government's version of employer-sponsored health insurance, but with the bargaining power of 65 million patients behind it. The program operates through four parts: Part A covers hospital stays (funded through payroll taxes), Part B covers doctor visits and outpatient care (funded through premiums and general revenue), Part C allows private insurers to offer Medicare plans (Medicare Advantage), and Part D covers prescription drugs. Unlike Medicaid, which serves low-income populations, Medicare serves all qualifying seniors regardless of wealth—making it both universal and politically untouchable.

How It Works in Practice

Let's examine how Medicare's reimbursement decisions move markets. In 2023, when Medicare announced it would cover Biogen's (BIIB) controversial Alzheimer's drug Aduhelm at $28,200 annually per patient, the stock jumped 8% in after-hours trading. Here's the math that matters:

Conversely, when Medicare proposed cutting reimbursements for outpatient procedures by 3.8% in 2022, hospital stocks like HCA Healthcare (HCA) and Tenet Healthcare (THC) dropped 4-6% within hours. Medicare Advantage enrollment tells another story—it's grown from 19% of Medicare beneficiaries in 2010 to 48% in 2023, creating a $400 billion market that benefits insurers like UnitedHealth Group (UNH) and Humana (HUM), which derive 65% and 75% of their revenues from government programs, respectively.

Why Smart Investors Care

Professional healthcare investors treat Medicare coverage decisions like earnings catalysts because they literally create or destroy billions in addressable market overnight. The program's Diagnosis Related Group (DRG) payment system—which pays hospitals fixed amounts based on patient diagnosis rather than services provided—fundamentally shapes hospital operating models and medical device adoption. Smart money watches the Medicare Payment Advisory Commission's annual reports for early signals on reimbursement changes. Here's the contrarian insight: Medicare's shift toward value-based care, where providers get paid for outcomes rather than volume, actually benefits high-quality operators with scale advantages. That's why consolidation plays in healthcare often outperform—companies like UnitedHealth can leverage their Medicare Advantage membership to negotiate better rates with providers while improving care coordination.

Common Mistakes to Avoid

The Bottom Line

Medicare isn't just a social program—it's the 800-pound gorilla that determines healthcare economics in America. Whether you're evaluating hospital stocks, pharmaceutical companies, or medical device manufacturers, understanding Medicare's payment methodologies and policy direction is essential for making informed investment decisions. As Medicare Advantage continues growing and value-based care models expand, which traditional healthcare business models will prove obsolete?